Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis
March 26, 2015 19:00 ET
|
Proteon Therapeutics, Inc.
DALLAS and WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of...
Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
October 15, 2014 11:39 ET
|
Wisconsin Alumni Research Foundation
MADISON, Wis., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Deltanoid Pharmaceuticals announces the successful completion of a phase 2B clinical trial for its lead experimental drug DP001 for the treatment of...